Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study
Open Access
- 15 February 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (4) , e41-e46
- https://doi.org/10.1086/596552
Abstract
Background. Vancomycin is the only US Food and Drug Administration–approved drug for treatment of Clostridium difficile infection (CDI). MetronidazolKeywords
This publication has 17 references indexed in Scilit:
- Growth and Geographic Variation in Hospitalizations with Resistant Infections, United States, 2000–2005Emerging Infectious Diseases, 2008
- Vancomycin for the Treatment ofClostridium difficileInfection: For Whom Is This Expensive Bullet Really Magic?Clinical Infectious Diseases, 2008
- Treatment ofClostridium difficileInfectionClinical Infectious Diseases, 2008
- A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-Associated Diarrhea, Stratified by Disease SeverityClinical Infectious Diseases, 2007
- New Drugs for Clostridium difficile InfectionClinical Infectious Diseases, 2006
- A Predominantly Clonal Multi-Institutional Outbreak ofClostridium difficile–Associated Diarrhea with High Morbidity and MortalityNew England Journal of Medicine, 2005
- Treatment of Clostridium difficile-associated disease: old therapies and new strategiesThe Lancet Infectious Diseases, 2005
- Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, CanadaClinical Infectious Diseases, 2005
- Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with MetronidazoleClinical Infectious Diseases, 2005
- A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone UseInfection Control & Hospital Epidemiology, 2005